TY - JOUR T1 - Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.1686 VL - 56 IS - suppl 64 SP - 1686 AU - Jana Skřičková AU - Petra Májková AU - Magda Bařinová AU - Monika Bratová AU - Miloš Pešek AU - Martin Svatoň AU - Vítězslav Kolek AU - Ondřej Fišer AU - Leona Koubková AU - Andrea Benejová AU - Ondřej Venclíček AU - Markéta Černovská AU - Libor Havel AU - Michal Hrnčiarik AU - Jaromír Roubec AU - Zemanová Milada AU - Petr Opálka AU - Jana Krejčí AU - Dan Krejčí AU - Helena Čoupková AU - Zdeněk Merta Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/1686.abstract N2 - Study evaluated the frequency of individual mutations before the start of the 1st and 2nd generation TKI treatment, and determined in what material the mutations were identified and what methods led to obtainig the best material.The TULUNG registry, containing data of all NSCLC patients (pts.) in the Czech Republic treated with TKI, was used. Up to 2019, 1st and 2nd-generation TKI treatment was initiated after diagnosis in 520 patients with NSCLC and activating mutations of EGFR.Most pts., 263 (50.6%) had mutation in exon 19; 133 (25.6%) in exon 21, 42 (8.1%) in exon 18, and 18 (3.5%) in exon 20. Another 61 (11.8%) pts. had mutations in multiple exons: 32 (52.5% of 61) in exons 19 and 20, 16 (26.2% of 61) in exons 20 and 21, in exons 18 and 19 - 1 pt. and in exons 18 and 20 - 3 pts.. Combination of 3 exons occurred twice (exons 18, 19 and 20; exons 19, 20 and 21). Seven (11.5% of 61) pts. had mutation on 4 exons (18, 19, 20, 21).Collection of material from primary tumor prevailed in 338 (65.0%) pts., followed by collection from metastasis in 42 (8.1%), pleural fluid in 38 (7.3%) and plasma in 30 (5.8%) pts.. The methods of material collection were balanced in terms of the number of individual options. The most common were transbronchial biopsies (TBB) – 90 (17.3%); 74 (14.2%) samples were obtained by intraluminal biopsy, 59 (11.3%) by transparietal biopsy, 59 (11.3%) by peroperative biopsy 25 (4.8%) by EBUS or EUS guided biopsy. Liquid biopsy samples were used in 25 (4.8%).EGFR mutations were most frequently found in exon 19 (263 pts.). Material was mostly collected from primary tumor. TBB was the most useful method.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1686.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -